Cargando…

Dual therapy with darunavir/r plus etravirine is safe and effective as switching therapy in antiretroviral experienced HIV-patients. The BITER Study

INTRODUCTION: Switching therapy studies are usually designed as second-line antiretroviral treatment (ART) in patients without previous virologic failures. Combined ART (cART) with DRV/r and ETR has a good pharmacokinetic profile, high genetic barrier and has been proved as rescue therapy. The aim o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Portilla, Joaquín, Arazo, Piedad, Crusells, Josefa, Pérez-Martínez, Laura, Martínez-Madrid, Onofre, Boix, Vicente, Moreno, Javier, Navarro, Vicente, Rubio, Teresa, Reus, Sergio, Galera, Carlos, Bernal, Enrique, Jover, Francisco, Amador, Concepcion, Baño, David, Merino, Esperanza, Saiz-de-la-Hoya, Pablo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P271
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225347/ https://www.ncbi.nlm.nih.gov/pubmed/25397547 http://dx.doi.org/10.7448/IAS.17.4.19803

Ejemplares similares

Symptômes respiratoires et anomalies radiologiques dans le COVID long
por: Jutant, E.M., et al.
Publicado: (2022)

Efficacy of a dual therapy based on darunavir/ritonavir and etravirine in ART-experienced patients
por: Ignacio Bernardino, Jose, et al.
Publicado: (2014)

Switching to dual therapy with darunavir/ritonavir and etravirine: a simplification strategy
por: Tyrer, M, et al.
Publicado: (2010)

Week 48 results of a Phase IV trial of etravirine with antiretrovirals other than darunavir/ritonavir in HIV-1-infected treatment-experienced adults
por: Arathoon, Eduardo, et al.
Publicado: (2014)

Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants
por: Moore, Katy, et al.
Publicado: (2022)

Are biters sick? Health status of tail biters in comparison to control pigs
por: Czycholl, I., et al.
Publicado: (2023)

Skin Biter: Dermatodaxia Revisited
por: Cohen, Philip R
Publicado: (2022)

Darunavir-based dual therapy in HIV experienced patients
por: Sterrantino, Gaetana, et al.
Publicado: (2014)

Interaction between Darunavir and Etravirine Is Partly Mediated by CYP3A5 Polymorphism
por: Belkhir, Leïla, et al.
Publicado: (2016)

Efficacy and safety of darunavir and etravirine in an antiretroviral multi-experienced youth with vertically HIV-1 infection
por: Rosso, R, et al.
Publicado: (2009)

Effectiveness and safety of dual therapy with rilpivirine and boosted darunavir in treatment-experienced patients with advanced HIV infection: a preliminary 24 week analysis (RIDAR study)
por: Pasquau, Juan, et al.
Publicado: (2019)

Rilpivirine versus etravirine validity in NNRTI-based treatment failure in Thailand
por: Teeranaipong, Phairote, et al.
Publicado: (2014)

Efficacy and tolerability of Etravirine in HIV-1 adult patients: Results of a large French prospective cohort
por: Allavena, Clotilde, et al.
Publicado: (2014)

A clinical and pharmacokinetic study of the combination of etravirine plus raltegravir in HIV patients with expanded intolerance or resistance
por: Bañón, Sara, et al.
Publicado: (2014)

Liver Fibrosis progression using Fibroscan in HIV/HCV coinfected patients with undetectable HIV viral load
por: Perez-Martinez, Laura, et al.
Publicado: (2014)

Pharmacokinetics and Pharmacodynamics of Darunavir and Etravirine in HIV-1–Infected, Treatment-Experienced Patients in the Gender, Race, and Clinical Experience (GRACE) Trial
por: Kakuda, Thomas, et al.
Publicado: (2012)

Monotherapy with darunavir/ritonavir is effective and safe in clinical practice
por: Pasquau, Juan, et al.
Publicado: (2014)

Efficacy and safety of etravirine-containing regimens in a large cohort of HIV/HCV coinfected patients according to liver fibrosis
por: Luis Casado, Jose, et al.
Publicado: (2014)

Switching to lamivudine plus darunavir/r dual therapy in a cohort of treatment-experienced HIV-positive patients: the experience of an Italian centre
por: Borghetti, Alberto, et al.
Publicado: (2014)

Impact of etravirine use on hospitalization rates among highly pre-treated failing HIV-1 infected individuals between 2005 and 2011
por: Lacombe, Jean-Marc, et al.
Publicado: (2014)

Protease mutations emerging on darunavir in protease inhibitor-naïve and experienced patients in the UK
por: El Bouzidi, Kate, et al.
Publicado: (2014)

The effects of Maraviroc on liver fibrosis in HIV/HCV co-infected patients
por: Ortega Gonzalez, Enrique, et al.
Publicado: (2014)

Role of Baseline HIV-1 DNA Level in Highly-Experienced Patients Receiving Raltegravir, Etravirine and Darunavir/Ritonavir Regimen (ANRS139 TRIO Trial)
por: Charpentier, Charlotte, et al.
Publicado: (2013)

Drug susceptibility to etravirine and darunavir among Human Immunodeficiency Virus Type 1-derived pseudoviruses in treatment-experienced patients with HIV/AIDS in South Korea
por: Kwon, Oh-Kyung, et al.
Publicado: (2015)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patients
por: Luis Casado, Jose, et al.
Publicado: (2014)

No difference in persistence to treatment with atazanavir or darunavir in HIV patients in a real-world setting
por: Farr, Amanda M, et al.
Publicado: (2014)

Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial
por: Arathoon, Eduardo, et al.
Publicado: (2017)

Profile of etravirine for the treatment of HIV infection
por: Tseng, Alice, et al.
Publicado: (2010)

Resistance mutations in protease gene at baseline are not related to virological failure in patients treated with darunavir/ritonavir monotherapy
por: Gutierrez-Liarte, Angela, et al.
Publicado: (2014)

Darunavir resistance spectrum in darunavir-na#239;ve patients harboring virological failure to antiretroviral therapy
por: Marcelin, AG, et al.
Publicado: (2010)

Etravirine Pharmacokinetics in HIV-Infected Pregnant Women
por: Mulligan, Nikki, et al.
Publicado: (2016)

Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial
por: Avihingsanon, Anchalee, et al.
Publicado: (2022)

Safety and therapeutic efficacy of the switch to maraviroc+darunavir/ritonavir in HIV/HCV coinfected patients: initial results from GUSTA study
por: Gagliardini, Roberta, et al.
Publicado: (2014)

Effectiveness and durability of darunavir/ritonavir (DRV/r) in DRV/r-experienced HIV-1-infected patients in routine clinical practice
por: Antinori, Andrea, et al.
Publicado: (2014)

Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach
por: Dickinson, Laura, et al.
Publicado: (2014)

RESISTANCE TO GLUCOCORTICOSTEROID THERAPY IN PATIENTS WITH SARS-COV-2 INFECTION WITH ELEVATED MARKERS OF ENDOTOXEMIA
por: Beloglazov, V., et al.
Publicado: (2022)

Comparison of oxidative stress markers in HIV-infected patients on efavirenz or atazanavir/ritonavir-based therapy
por: Estrada, Vicente, et al.
Publicado: (2014)

The experience of physiotherapy and occupational therapy students of pandemic teaching and its perceived impact on placement/practice
por: Benham, A., et al.
Publicado: (2022)

Efficacy of a reduced dose of DARUNAVIR/RTV in a cohort of antiretroviral-naïve and experienced HIV-infected patients: a medium-term follow-up
por: Lanzafame, Massimiliano, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_f3ee1kh8rneai8iaf4v4evd9r9